The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization

OBJECTIVES: The primary objective is to evaluate the comparative effectiveness of COVID-19 specific monoclonal antibodies (mABs) with US Food and Drug Administration (FDA) Emergency Use Authorization (EUA), alongside UPMC Health System efforts to increase patient access to these mABs. TRIAL DESIGN:...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, David T., McCreary, Erin K., Bariola, J. Ryan, Wadas, Richard J., Kip, Kevin E., Marroquin, Oscar C., Koscumb, Stephen, Collins, Kevin, Shovel, Judith A., Schmidhofer, Mark, Wisniewski, Mary Kay, Sullivan, Colleen, Yealy, Donald M., Axe, Meredith, Nace, David A., Haidar, Ghady, Khadem, Tina, Linstrum, Kelsey, Snyder, Graham M., Seymour, Christopher W., Montgomery, Stephanie K., McVerry, Bryan J., Berry, Lindsay, Berry, Scott, Meyers, Russell, Weissman, Alexandra, Peck-Palmer, Octavia M., Wells, Alan, Bart, Robert, Albin, Debbie L., Minnier, Tami, Angus, Derek C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144687/
https://www.ncbi.nlm.nih.gov/pubmed/34034784
http://dx.doi.org/10.1186/s13063-021-05316-3

Ejemplares similares

Ejemplares similares